RHEUMATOID ARTHRITIS AND THE COMPLEMENT SYSTEM
PDF EN
PDF BG (Български)

How to Cite

[1]
KOSTURKOVA, M., RADANOVA, M., MIHAYLOVA, G. and KADINOV, V. 2020. RHEUMATOID ARTHRITIS AND THE COMPLEMENT SYSTEM. Revmatologiia (Bulgaria). 28, 4 (Dec. 2020), 45-58. DOI:https://doi.org/10.35465/28.4.2020.pp45-58.

Abstract

The complement system represents a major part of the immune response. Its normal functioning is mandatory for the organism’s defence against pathogens and for the clearance of immune complexes, apoptotic cells and cellular debris. Its over-activation however can lead to generation of many pro-inflammatory and cytotoxic mediators, causing inflammation and tissue damage. The participation of the complement system in rheumatoid arthritis’(RA) pathogenesis is indisputable but its intimate mechanisms and the opportunities for influencing them are still an object of investigation. The aim of this review is to outline and systematize all the relevant scientific evidence.

https://doi.org/10.35465/28.4.2020.pp45-58
PDF EN
PDF BG (Български)

References

    Okroj M. et al. Rheumatoid Arthritis and the Complement System. Ann Med. 2007;39(7):517-30.doi: 10.1080/07853890701477546
    2. Nauta AJ, Castellano G, Xu W, Woltman AM, Borrias MC, Daha MR, et al. Opsonization with C1q and mannose-binding lectin targets apoptotic cells to dendritic cells. J Immunol 2004;173:3044–50. doi: 10.4049/jimmunol.173.5.3044
    3. Chen M, Daha MR, Kallenberg CG. The complement system in systemic autoimmune disease. J Autoimmun 2010;34:J276–86. doi: 10.1016/j.jaut.2009.11.014
    4. Walport MJ. Complement. First of two parts. N Engl J Med 2001;344:1058–66. 10.1056/NEJM200104053441406
    5. Miura N, Prentice HL, Scheider PM, Perlmutter DH. Synthesis and regulation of the two human complement C4 genes in stable transfected mouse fibroblasts. J Biol Chem 1987;262:7298–305,
    6. Andus T, Heinrich PC, Bauer J, Trau-Thi TA, Decker K, Manuel D, et al. Discrimination of hepatocyte stimulating activity from human recombinant tumour necrosis factor a. Eur J Immunol 1988;17:1193–7;
    7. Anthony R, EL-Omar E, Lappin DF, MacSween RNM, Whaley K. Regulation of hepatic synthesis of C3 and C4 during acute-phase response in the rat. Eur J Immunol 1989;19:1405–12;
    8. Ramadori G, Van Daume J, Riedert H, Mayer Zum Buschenfelde KH. Interleukin-6, the third mediator of acute-phase reaction, modulates hepatic protein synthesis in human and mouse comparison as with interleukin-1β and tumour necrosis faclor-α. Eur J Immunol 1988;18:1259–64
    9. Ruddy S, Colten HR. Rheumatoid arthritis. Biosynthesis of complement proteins by synovial tissues. N Engl J Med 1974;290:1284–8
    10. Moffat GJ, Lappin D, Birnie GD, Whaley K. Complement biosythesis in human synovial tissue. Clin Exp Immunol 1989;78:54–60
    11. Cohen HR. Biosynthesis of complement. Biosynthesis of complement. Adv lmmunol 1976;22:67–118;
    12. Cook KS, Min HY, Johnson D, Chaplinsky RJ, Frier JS, Hunt CR, et al. Adipsin: a circulating serine protease homology secreted by adipose tissue and sciatic nerve. Science 1987;237:402–8;
    13. Morris KM, Aden DP, Knowles BB, Colten HR. Complement biosynthesis by the human hepatoma-derived cell line HepG2. J Clin Invest 1982;70:906–13
    14. Whaley K, Guc D, Gulati P, Lappin D. Synthesis of complement components by synovial membrane. Immunopharmacology 1992;24:83–9
    15. Bradley, K.; North, J.; Saunders, D.; Schwaeble, W.; Jeziorska, M.; Woolley, D. E.; Whaley, K. Synthesis of classical pathway complement components by chondrocytes. Immunology 1996, 88, 648-656;
    16. Nakagawa, K.; Sakiyama, H.; Tsuchida, T.; Yamaguchi, K.; Toyoguchi, T.; Masuda, R.; Moriya, H. Complement C1s activation in degenerating articular cartilage of rheumatoid arthritis patients: immunohistochemical studies with an active form specific antibody. Ann. Rheum. Dis. 1999, 58, 175-181;
    17. Khan, I. M.; Salter, D. M.; Bayliss, M. T.; Thomson, B. M.; Archer, C. W. Expression of clusterin in the superficial zone of bovine articular cartilage. Arthritis Rheum. 2001, 44, 1795-1799; doi: 10.1002/1529-0131(200108)44:8<1795::AID-ART316>3.0.CO;2-K
    18. Andrades, J. A.; Nimni, M. E.; Becerra, J.; Eisenstein, R.; Davis, M.; Sorgente, N. Complement proteins are present in developing endochondral bone and may mediate cartilage cell death and vascularization. Exp. Cell Res. 1996, 227, 208-213
    19. Garred, P.; Hetland, G.; Mollnes, T. E.; Stoervold, G. Scand. Synthesis of C3, C5, C6, C7, C8, and C9 by Human Fibroblasts. J. Immunol. 1990, 32, 555-560
    20. Onuma, H.; Masuko-Hongo, K.; Yuan, G.; Sakata, M.; Nakamura, H.; Kato, T.; Aoki, H.; Nishioka, K. Expression of the anaphylatoxin receptor C5aR (CD88) by human articular chondrocytes. Rheumatol. Int. 2002, 22, 52 – 55; doi: 10.1007/s00296-002-0199-6
    21. Kiener, H. P.; Baghestanian, M.; Dominkus, M.; Walchshofer, S.; Ghannadan, M.; Willheim, M.; Sillaber, C.; Graninger, W. B.; Smolen, J. S.; Valent, P. Expression of the C5a receptor (CD88) on synovial mast cells in patients with rheumatoid arthritis. Arthritis Rheum. 1998, 41, 233-245; doi: 10.1002/1529-0131(199802)41:2<233::AID-ART7>3.0.CO;2-V
    22. Neumann, E.; Barnum, S. R.; Tarner, I. H.; Echols, J.; Fleck, M.; Judex, M.; Kullmann, F.; Mountz, J. D.; Scholmerich, J.; Gay, S. Local production of complement proteins in rheumatoid arthritis synovium. Arthritis Rheum. 2002, 46, 934-945; doi: 10.1002/art.10183
    23. De Ceulaer, C.; Papazoglou, S.; Whaley, K. Increased biosynthesis of complement components by cultured monocytes, synovial fluid macrophages and synovial membrane cells from patients with rheumatoid arthritis. Immunology 1980, 41, 37-43
    24. Brodeur JP, Ruddy S, Schwartz LB, Moxley G. Synovial fluid levels of complement SC5b-9 and fragment Bb are elevated in patients with rheumatoid arthritis. Arthritis Rheum 1991;34:1531–7
    25. Guc D, Gulati P, Lemercier C, Lappin D, Birnie GD, Whaley K. Expression of the components and regulatory proteins of the alternative complement pathway and the membrane attack complex in normal and diseased synovium. Rheumatol Int 1993;13:139–46
    26. Coleman, P. J.; Scott, D.; Ray, J.; Mason, R. M.; Levick, J. R. Hyaluronan secretion into the synovial cavity of rabbit knees and comparison with albumin turnover. J. Physiol. 1997, 503, 645-656
    27. Mizuno, M.; Nishikawa, K.; Goodfellow, R. M.; Piddlesden, S. J.; Morgan, B. P.; Matsuo, S. The effects of functional suppression of a membrane‐bound complement regulatory protein, CD59, in the synovial tissue in rats. Arthritis Rheum. 1997, 40, 527-533
    28. Mizuno, M.; Nishikawa, K.; Morgan, B. P.; Matsuo, S. Comparison of the suppressive effects of soluble CR1 and C5a receptor antagonist in acute arthritis induced in rats by blocking of CD59 Clin. Exp. Immunol. 2000, 119, 368-375; doi: 10.1046/j.1365-2249.2000.01127.x
    29. Morgan, K.; Clague, R. B.; Shaw, M. J.; Firth, S. A.; Twose, T. M. Native Type II Collagen‐Induced Arthritis in the Rat; Arthritis Rheum. 1981, 24, 1356-1362.
    30. Kerwar, S. S.; Bauman, N.; Oronsky, A. L.; Sloboda, A. E. Studies on type II collagen induced polyarthritis in rats. Effect of complement depletion J. Immunopharmacol. 1981, 3, 323-337.
    31. Goodfellow, R. M.; Williams, A. S.; Levin, J. L.; Williams, B. D.; Morgan, B. P. Soluble complement receptor one (sCR1) inhibits the development and progression of rat collagen‐induced arthritisClin. Exp. Immunol. 2000, 119, 210-216; DOI: 10.1046/j.1365-2249.2000.01129.x
    32. Makinde VA, Senaldi G, Jawad AS, Berry H, Vergani D. Reflection of disease activity in rheumatoid arthritis by indices of activation of the classical complement pathway. Ann Rheum Dis 1989;48:302–6.
    33. Hietala MA, Nandakumar KS, Persson L, Fahlen S, Holmdahl R, Pekna M. Complement activation by both classical and alternative pathways is critical for the effector phase of arthritis. Eur J Immunol 2004;34:1208–16; doi: 10.1002/eji.200424895
    34. Petersen NE, Elmgreen J, Teisner B, Svehag SE. Activation of classical pathway complement in chronic inflammation: elevated levels of circulating C3d and C4d split products in rheumatoid arthritis and Crohn's disease. Acta Med Scand 1988;223:557–60
    35. Zubler RH, Nydegger U, Perrin LH, Fehr K, McCormick J, Lambert PH, et al. Circulating and intra-articular immune complexes in patients with rheumatoid arthritis: correlation of 125IClq binding activity with clinical and biological features of the disease. J Clin Invest 1976;57:1308–19.
    36. Hay FC, Nineham LJ, Perumal R, Roitt IM. Intra-articular and circulating immune complexes and antiglobulins (IgG and IgM) in rheumatoid arthritis: correlation with clinical features. Ann Rheum Dis 1979;38:1–7
    37. Robbins DL, Fiegal Jr DW, Leek JC, Shapiro R, Wiesner K. Complement activation by 19S IgM rheumatoid factor: relationship to disease activity in rheumatoid arthritis. J Rheumatol 1986;13:33–8.
    38. Sato Y, Sato R, Watanabe H, Kogure A, Watanabe K, Nishimaki T, et al. Complement activating properties of monoreactive and polyreactive IgM rheumatoid factors. Ann Rheum Dis 1993;52:795–800.
    39. Sato Y, Watanabe H, Kogure A, Miyata M, Watanabe K, Nishimaki T, et al. Complement-activating properties of IgM rheumatoid factors reacting with IgG subclasses. Clin Rheumatol 1995;14:425–8.
    40. Tanimoto K, Cooper NR, Johnson JS, Vaughan JH. Complement fixation by rheumatoid factor. J Clin Invest 1975;55:437–45
    41. Sabharwal UK, Vaughan JH, Fong S, Bennett PH, Carson DA, Curd JG. Activation of the classical pathway of complement by rheumatoid factors: assessment by radioimmunoassay for C4. Arthritis Rheum 1982;25:161–7
    42. Trouw LA, Haisma EM, Levarht EW, van der Woude D, Ioan-Facsinay A, Daha MR, et al. Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. Arthritis Rheum 2009;60:1923–31; doi: 10.1002/art.24622
    43. Volonakis JE. Complement activation by C-reactive protein complexes. Ann NY Acad Sci 1982;389:235–49.
    44. Wolbink GJ, Brouwer MC, Buysman S, ten Berge IJM, Hack CE. CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes. J Immunol 1996;157:473–9.
    45. Lagrand WK, Niessen HWM, Wolbink GJ, Jaspers LH, Visser CA, Verheugt FWA, et al. C-reactive protein co-localizes with complement in human hearts during acute myocardial infarction. Circulation 1997;95:97–103.
    46. Wolbink GJ, Bossink AWJ, Groeneveld ABJ, de Groot MCM, Thijs LG, Hack CE. Complement activation in patients with sepsis is in part mediated by C-reactive protein. J Infect Dis 1998;177:81–7; DOI: 10.1086/513803
    47. Molenaar ET, Voskuyl AE, Familian A, van Mierlo GJ, Dijkmans BA, Hack CE. Complement activation in patients with rheumatoid arthritis mediated in part by C-reactive protein. Arthritis Rheum 2001;44:997–1002
    48. Doherty M, Richards N, Hornby J, Powell R. Relation between synovial fluid C3 degradation products and local joint inflammation in rheumatoid arthritis, osteoarthritis, and crystal associated arthropathy. Ann Rheum Dis 1988;47:190–7.
    49. Oleesky DA, Daniels RH, Williams BD, Amos N, Morgan BP. Terminal complement complexes and C1/C1 inhibitor complexes in rheumatoid arthritis and other arthritic conditions. Clin Exp Immunol 1991;84:250–5.
    50. Konttinen YT, Ceponis A, Meri S, Vuorikoski A, Kortekangas P, Sorsa T, et al. Complement in acute and chronic arthritides: assessment of C3c, C9, and protectin (CD59) in synovial membrane. Ann Rheum Dis 1996;55:888–94.
    51. Jose PJ, Moss IK, Maini RN, Williams TJ. Measurement of the chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: role of C5a in the acute inflammatory phase. Ann Rheum Dis 1990;49:747–52
    52. Morgan BP, Daniels RH, Williams BD. Measurement of terminal complement complexes in rheumatoid arthritis. Clin Exp Immunol. 1988;73:473–8.
    53. Swaak AJ, Van Rooyen A, Planten O, Han H, Hattink O, Hack E. An analysis of the levels of complement components in the synovial fluid in rheumatic diseases. Clin Rheumatol. 1987;6:350–7.
    54. Corvetta A, Pomponio G, Rinaldi N, Luchetti MM, Di Loreto C, Stramazzotti D. Terminal complement complex in synovial tissue from patients affected by rheumatoid arthritis, osteoarthritis and acute joint trauma. Clin Exp Rheumatol. 1992;10:433–8.
    55. Hogasen K, Mollnes TE, Harboe M, Gotze O, Hammer HB, Oppermann M. Terminal complement pathway activation and low lysis inhibitors in rheumatoid arthritis synovial fluid. J Rheumatol. 1995;22:24–8.
    56. Moxley G, Ruddy S. Elevated C3 anaphylatoxin levels in synovial fluids from patients with rheumatoid arthritis. Arthritis Rheum. 1985;28:1089–95.
    57. Jose PJ, Moss IK, Maini RN, Williams TJ. Measurement of the chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: role of C5a in the acute inflammatory phase. Ann Rheum Dis. 1990;49:747–52
    58. Lark MW, Bayne EK, Flanagan J, Harper CF, Hoerrner LA, Hutchinson NI, et al. Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints. J Clin Invest. 1997;100:93–106.
    59. Woolley DE, Tetlow LC. Observations on the microenvironmental nature of cartilage degradation in rheumatoid arthritis. Ann Rheum Dis. 1997;56:151–61.
    60. Tetlow LC, Harper N, Dunningham T, Morris MA, Bertfield H, Woolley DE. Effects of induced mast cell activation on prostaglandin E and metalloproteinase production by rheumatoid synovial tissue in vitro. Ann Rheum Dis. 1998;57:25–32; doi: 10.1136/ard.57.1.25
    61. Morgan B P, Daniels R H, and Williams B D. Measurement of terminal complement complexes in rheumatoid arthritis. Clin. Exp. Immunol. 1988, 1988, 473-478
    62. Daniels RH, Williams BD, Morgan BP. Human rheumatoid synovial cell stimulation by the membrane attack complex and other pore-forming toxins in vitro: the role of calcium in cell activation. Immunology 1990, 71, 312-316
    63. Jahn B, Von Kempis J, Krämer K L, Filsinger S, and Hänsch G M. Interaction of the terminal complement components C5b-9 with synovial fibroblasts: binding to the membrane surface leads to increased levels in collagenase-specific mRNA. Immunology 1993, 78, 329-334
    64. Mollnes TE, Lea T, Mellbye OJ, Pahle J, Grand O, Harboe M. Complement activation in rheumatoid arthritis evaluated by C3dg and the terminal complement complex. Arthritis Rheum 1986;29:715–21.
    65. Olmez U, Garred P, Mollnes TE, Harboe M, Berntzen HB, Munthe E. C3 activation products, C3 containing immune complexes, the terminal complement complex and native C9 in patients with rheumatoid arthritis. Scand J Rheumatol 1991;20:183–9
    66. Wouters D, Voskuyl AE, Molenaar ET, Dijkmans BA, Hack CE. Evaluation of classical complement pathway activation in rheumatoid arthritis: measurement of C1q–C4 complexes as novel activation products. Arthritis Rheum 2006;54:1143–50; doi: 10.1002/art.21729
    67. Aggarwal A, Bhardwaj A, Alam S, Misra R. Evidence for activation of the alternate complement pathway in patients with juvenile rheumatoid arthritis. Rheumatology (Oxford). 2000;39:189–92; doi: 10.1093/rheumatology/39.2.189
    68. Jarvis JN, Taylor H, Iobidze M, Krenz M. Complement activation and immune complexes in children with polyarticular juvenile rheumatoid arthritis: a longitudinal study. J Rheumatol. 1994;21:1124–7
    69. Schaapherder AF, Gooszen HG, te Bulte MT, Daha MR. Human complement activation via the alternative pathway on porcine endothelium initiated by IgA antibodies. Transplantation. 1995;60:287–91
    70. Jarvis JN, Iobidze M, Taylor H, DeJonge J, Chang S. A comparison of immunoglobulin G-containing highmolecular- weight complexes isolated from children with juvenile rheumatoid arthritis and congenital human immunodeficiency virus infection. Pediatr Res. 1993;34:781–4
    71. van Zeben D, Hazes JM, Zwinderman AH, Cats A, van der Voort EA, Breedveld FC. Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow up study. Ann Rheum Dis. 1992;51:1029–35
    72. Hanauske-Abel HM, Pontz BF, Schorlemmer HU. Cartilage specific collagen activates macrophages and the alternative pathway of complement: evidence for an immunopathogenic concept of rheumatoid arthritis. Ann Rheum Dis. 1982;41:168–76
    73. Sjoberg A, Onnerfjord P, Morgelin M, Heinegard D, Blom AM. The extracellular matrix and inflammation: fibromodulin activates the classical pathway of complement by directly binding C1q. J Biol Chem. 2005;280:32301–8; doi: 10.1074/jbc.M504828200
    74. Bengtsson E, Neame PJ, Heinegard D, Sommarin Y. The primary structure of a basic leucine-rich repeat protein, PRELP, found in connective tissues. J Biol Chem. 1995;270:25639–44
    75. Groeneveld TW, Oroszlan M, Owens RT, Faber-Krol MC, Bakker AC, Arlaud GJ, et al. Interactions of the extracellular matrix proteoglycans decorin and biglycan with C1q and collectins. J Immunol. 2005;175:4715–23; doi: 10.4049/jimmunol.175.7.4715
    76. Barilla ML, Carsons SE. Fibronectin fragments and their role in inflammatory arthritis. Semin Arthritis Rheum. 2000;29:252–65; doi: 10.1016/s0049-0172(00)80012-8
    77. Krumdieck R, Hook M, Rosenberg LC, Volanakis JE. The proteoglycan decorin binds C1q and inhibits the activity of the C1 complex. J Immunol. 1992;149:3695–701
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.